Загрузка...
Cardiovascular effects of antiobesity drugs: are the new medicines all the same?
Waiting for a definite answer from well-designed randomized prospective clinical trials, the impact of the new antiobesity drugs -liraglutide, bupropion/naltrexone, phentermine/topiramate and lorcaserin- on cardiovascular outcomes remains uncertain. What has been learned from previous experience wit...
Сохранить в:
| Опубликовано в: : | Int J Obes Suppl |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group UK
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7371629/ https://ncbi.nlm.nih.gov/pubmed/32714509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41367-020-0015-3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|